Furthermore, key JDM candidate biomarkers, both known (CXCL11 or I-TAC, MCP-1 and CXCL10 or IP-10) and novel ones (Angiopoetin-2, IL-22 and IL17B) were confirmed by ELISA assay for the untreated children with JDM further supporting the validity of this pilot data. This evidence concerns the gene CXCL10 and juvenile dermatomyositis.